AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03666702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb physiotherapy programme
Description: Web-based physio programme
Study NCT03666702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual physiotherapy care
Study NCT03666702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual physiotherapy care
Study NCT02588755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE+Tegafur
Description: Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
Study NCT02588755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE alone
Study NCT04411095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measuring thoracic rotation mobility
Description: Measuring the thoracic rotation mobility with a goniometer, from a standardized position
Study NCT04411095 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Measuring thoracic rotation mobility
Description: Measuring the thoracic rotation mobility with a goniometer, from a standardized position
Study NCT02148770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
Study NCT02148770 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback
Description: Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
Study NCT01047397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1278863A
Description: 25mg, 50mg, 100mg
Study NCT01047397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT00400205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
Study NCT00400205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
Study NCT00400205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
Study NCT04076137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted T-cell armed with bispecific antibody (Decitabine)
Description: In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.
Study NCT04352530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Communication
Description: Spoken word poems set to images performed by youth who wrote the poems. Videos were produced by The Bigger Project and were posted publicly to the Bigger Picture Project website and YouTube. Duration of videos ranges from 2 minutes to 6 minutes.
Study NCT02405104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorzoxazone
Description: ATC-code: M03BB03
Study NCT02405104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02405104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: THA
Description: Surgical treatment of osteoarthrosis in the hip, by replacement.
Study NCT02405104 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: THA
Description: Surgical treatment of osteoarthrosis in the hip, by replacement.
Study NCT02405104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA
Description: Surgical treatment of osteoarthrosis in the knee, by replacement.
Study NCT02405104 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TKA
Description: Surgical treatment of osteoarthrosis in the knee, by replacement.
Study NCT03068390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RICHH Intervention
Description: Whole health cardiovascular disease (CVD) self-care risk reduction intervention
Study NCT03068390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Referral to primary care provider
Study NCT03818633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Description: Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
Study NCT04768998 — intervention group
Intervention type: OTHER
Intervention: Observational of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings
Description: Observatory Cohorts focusing (I) on subjects after SARS-CoV-2 infection that are recruited from the general population (POP), and on subjects with acute SARS-CoV-2 infections recruited (II) in university hospital high-care settings or (III) general health care.
Study NCT04352530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Communication
Description: Spoken word poems set to images performed by youth who wrote the poems. Videos were produced by The Bigger Project and were posted publicly to the Bigger Picture Project website and YouTube. Duration of videos ranges from 2 minutes to 6 minutes.
Study NCT06123416 — intervention group
Intervention type: BEHAVIORAL
Intervention: Expressive Writing
Description: Caregivers complete three 20-min writing sessions in which they write about an assigned topic - emotional or non-emotional.
Study NCT03653078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three dimensional printed digital guide
Description: A CAD/CAM printed plate with a channel for mini-screw insertion
Study NCT01421368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% vaginal gel
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
Study NCT01196234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin/Gefitinib
Description: paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
Study NCT01196234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel/Carboplatin
Description: paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
Study NCT01421368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA)
Description: DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
Study NCT00842036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement and Family Training
Description: Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
Study NCT00842036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Entry Training
Description: Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
Study NCT00842036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12- step Al/Nar- Anon Facilitation
Description: The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
Study NCT02988557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: walking on a treadmill with a sloped surface
Description: walking on a treadmill with a sloped surface
Study NCT01421368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive: LNG 150 mcg and EE 30 mcg
Description: Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
Study NCT02988557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Description: walking on a treadmill with a sloped surface
Study NCT03116815 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Direct input of home blood pressure readings via MyChart
Description: Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
Study NCT03593447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin
Description: Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg
Study NCT03593447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin
Description: Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg
Study NCT03593447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-cirrhotic subjects. low TG-2349+ low DAG181
Description: Group 3: TG-2349 200 mg + DAG181 100 mg
Study NCT03593447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-cirrhotic subjects. high TG-2349+ high DAG181
Description: Group 4: TG-2349 400 mg + DAG181 200 mg
Study NCT04235465 — intervention group
Intervention type: OTHER
Intervention: Dynamic Gait Index
Description: The Dynamic Gait Index (DGI) measures functionality and dynamic balance in walking and stair climbing. The DGI consists of 8 items including normal gait on flat ground, gait with speed changes, gait with horizontal head movements, gait with vertical head movements, gait and pivot turn, gait and step over an obstacle, gait around obstacles and steps up and downstairs. The performance on each item is rated on a 4-point scale ranging from 0 (severe disorder) to 3 (independent walking). The total score is 24.
Study NCT03593447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin
Description: Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg_
Study NCT03593447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirrhotic subjects. high TG-2349+ high DAG181
Description: Group6: TG-2349 400 mg + DAG181 200 mg
Study NCT04253860 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical neurostimulation
Description: Sessions of 30 minutes of TENS will be applied three times a week during 90 days
Study NCT04253860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical neurostimulation
Description: Sessions of 30 minutes of TENS will be applied three times a week during 90 days
Study NCT02398123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
Study NCT02398123 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caudal block
Description: Children who received caudal 0.25% bupivacaine 1 mL/kg
Study NCT02398123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Study NCT02398123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT03424551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibrator
Description: Local or whole body vibration was applied at six different frequencies
Study NCT01652833 — intervention group
Intervention type: OTHER
Intervention: Physician Survey
Description: Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
Study NCT03600753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: culturomic
Description: Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
Study NCT03600753 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: culturomic
Description: Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
Study NCT00560404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms sc monthly (starting dose)
Study NCT00560404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: As prescribed
Study NCT01827943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus
Study NCT00501085 — intervention group
Intervention type: DEVICE
Intervention: LAP-BAND AP Adjustable Gastric Banding System
Description: Reduction of food intake due to creation of smaller stomach pouch.
Study NCT02975453 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: As prescribed by the treating physician
Study NCT04759092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.
Study NCT04992741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education and motivational interview
Description: The control group will remain subject to the routine process without any intervention.
Study NCT04309448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training with functional electrical stimulation
Description: The PBT program will consist of repetitive practice of reactive stepping for one hour. The participants will be equipped with the Odstock 2-Channel stimulator on one or both sides depending on their deficits. One channel of stimulation may be applied to the common fibular nerve to elicit a flexor withdraw reflex and elicit a step. The second channel of stimulation may be applied to the quadriceps muscles to assist with the supporting phase of the reactive step, as required. Participants will experience about 60 perturbations per session during balance exercises. To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness around the participant's trunk. Throughout the hour-long session, participants will complete challenging balance tasks, customized to their ability level, during standing and walking. The training will be supervised by a licensed physiotherapist and administered by a licensed physiotherapist or registered kinesiologist.
Study NCT03600753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: culturomic
Description: Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
Study NCT03600753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metagenomic
Description: Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
Study NCT03600753 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Metagenomic
Description: Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
Study NCT03600753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metagenomic
Description: Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
Study NCT03092037 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: The Investigators will collect serum and whole blood from participants.
Study NCT03873363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS TKA
Description: Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
Study NCT03873363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CR TKA
Description: Implantation of a cruciate retaining Total Knee Arthroplasty.
Study NCT02448862 — intervention group
Intervention type: DEVICE
Intervention: Fentanyl based IV-PCA
Description: We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
Study NCT00960414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHINE
Description: Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
Study NCT00960414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHINE
Description: Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
Study NCT00537095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 300 mg oral once daily oral dose
Study NCT00537095 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01444053 — intervention group
Intervention type: DEVICE
Intervention: No Intervention
Description: No Intervention
Study NCT03684330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: a dose once a week
Study NCT03684330 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: whole body vibration (WBV)
Description: 03 months of WBV training three times per week
Study NCT04008381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo Expanded γδ T Lymphocytes
Description: Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2\*10\^6, 4\*10\^6, 8\*10\^6 of cells per kg of body weight).
Study NCT01676363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diflunisal
Description: Open-label diflunisal 500 mg twice daily for 4 weeks
Study NCT00305825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00305825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole